Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07079644 · ClinicalTrials.gov registry record
Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 678
- Enrollment target
NCT07079644: Completed study, sponsored by Bristol-Myers Squibb.
NCT07079644 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 678 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07079644 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 678 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the real-world clinical outcomes of individuals that have been diagnosed with advanced melanoma who were treated with Nivolumab in combination with Relatlimab, Nivolumab in combination with Ipilimumab, immuno-oncology monotherapy or BRAF/MEK inhibitors therapy
Interventions
- BIOLOGICAL Nivolumab + Relatlimab
- BIOLOGICAL Nivolumab + Ipilimumab
- BIOLOGICAL Immunotherapy monotherapy
- DRUG BRAF/MEK inhibitors
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 678 participants |
| Start Date | 2024-11-29 |
| Est. Completion | 2025-03-31 |
What the finished NCT07079644 record still lists
NCT07079644 is an observational study that tracks outcomes without assigning an intervention. The registered 678 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 4 interventions - of which Nivolumab + Relatlimab is the first listed.
NCT07079644 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07079644 about?
NCT07079644 is a clinical study titled "Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database". The purpose of this study is to investigate the real-world clinical outcomes of individuals that have been diagnosed with advanced melanoma who were treated with Nivolumab in combination with Relatlimab, Nivolumab in combination with Ipilimumab, immuno-oncology monotherapy or BRAF/MEK inhibitors the...
What is the current status of trial NCT07079644?
This trial is currently completed. The enrollment target is 678 participants. The study started on 2024-11-29. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT07079644?
The interventions under investigation include: Nivolumab + Relatlimab (BIOLOGICAL), Nivolumab + Ipilimumab (BIOLOGICAL), Immunotherapy monotherapy (BIOLOGICAL), BRAF/MEK inhibitors (DRUG).
Who is sponsoring clinical trial NCT07079644?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05372484 · 678 participants · NA
Rice Technologies for Cervical Cancer Screening and Diagnosis
- NCT06436924 · 678 participants
Safety and Efficacy of Workflows of High Volume Single Operators in a LAAO Device Implant Procedural Day
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI